Pacira BioSciences, Inc. — Director's Dealing 2017

Jan 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2017-01-17

Reporting Person: Scibetta James S (President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-17	Common Stock	M	2373	$1.61	Acquired	29457	Direct
2017-01-17	Common Stock	M	17627	$5.49	Acquired	47084	Direct
2017-01-17	Common Stock	S	15003	$38.39	Disposed	32081	Direct
2017-01-17	Common Stock	S	4997	$38.97	Disposed	27084	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-17	Stock Option (Right to Buy)	$1.61	M	2373	Disposed	2020-09-02	Common Stock (2373)	Direct
2017-01-17	Stock Option (Right to Buy)	$5.49	M	17627	Disposed	2020-12-29	Common Stock (17627)	Direct

Footnotes

F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.75, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.05, inclusive.

F4: The option vested as to 50% of the options on September 2, 2010 and vests as to the remaining options in successive equal monthly installments for the subsequent 24 months. The options become exercisable, to the extent vested, from and after the issuer's initial public offering.

F5: The option vests as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. The option shares become exercisable, to the extent vested, from and after the Issuer's initial public offering.